

# Paul J Hoskins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4568246/publications.pdf>

Version: 2024-02-01

28  
papers

1,056  
citations

758635

12  
h-index

552369

26  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1384  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase II Study of Temsirolimus in Women With Recurrent or Metastatic Endometrial Cancer: A Trial of the NCIC Clinical Trials Group. <i>Journal of Clinical Oncology</i> , 2011, 29, 3278-3285.	0.8	321
2	Paclitaxel and Carboplatin, Alone or With Irradiation, in Advanced or Recurrent Endometrial Cancer: A Phase II Study. <i>Journal of Clinical Oncology</i> , 2001, 19, 4048-4053.	0.8	283
3	Low-Stage Ovarian Clear Cell Carcinoma: Population-Based Outcomes in British Columbia, Canada, With Evidence for a Survival Benefit As a Result of Irradiation. <i>Journal of Clinical Oncology</i> , 2012, 30, 1656-1662.	0.8	109
4	Missed therapeutic and prevention opportunities in women with BRCA-mutated epithelial ovarian cancer and their families due to low referral rates for genetic counseling and BRCA testing: A review of the literature. <i>Ca-A Cancer Journal for Clinicians</i> , 2017, 67, 493-506.	157.7	58
5	Carboplatin plus paclitaxel for advanced or recurrent uterine malignant mixed müllerian tumors. The British Columbia Cancer Agency experience. <i>Gynecologic Oncology</i> , 2008, 108, 58-62.	0.6	55
6	Evolution of genetic assessment for BRCA-associated gynaecologic malignancies: a Canadian multisociety roadmap. <i>Journal of Medical Genetics</i> , 2018, 55, 571-577.	1.5	33
7	R-CHOP with Etoposide Substituted for Doxorubicin (R-CEOP): Excellent Outcome in Diffuse Large B Cell Lymphoma for Patients with a Contraindication to Anthracyclines.. <i>Blood</i> , 2009, 114, 408-408.	0.6	28
8	Identifying patients unlikely to benefit from further chemotherapy: A descriptive study of outcome at each relapse in ovarian cancer. <i>Gynecologic Oncology</i> , 2005, 97, 862-869.	0.6	20
9	Population-based treatment and outcomes of Stage I uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2014, 132, 61-64.	0.6	19
10	Combined methotrexate-dactinomycin: An effective therapy for low-risk gestational trophoblastic neoplasia. <i>Gynecologic Oncology</i> , 2012, 124, 553-557.	0.6	18
11	Early-Stage Endometrioid Ovarian Carcinoma: Population-Based Outcomes in British Columbia. <i>International Journal of Gynecological Cancer</i> , 2014, 24, 1401-1405.	1.2	18
12	Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) Patients with a Negative Pet Scan Following Three Cycles of R-CHOP Can Be Effectively Treated with Abbreviated Chemoimmunotherapy Alone.. <i>Blood</i> , 2007, 110, 787-787.	0.6	16
13	Canadian cost-effectiveness model of BRCA-driven surgical prevention of breast/ovarian cancers compared to treatment if cancer develops. <i>International Journal of Technology Assessment in Health Care</i> , 2020, 36, 104-112.	0.2	13
14	Targeted surgical prevention of epithelial ovarian cancer is cost effective and saves money in BRCA mutation carrying family members of women with epithelial ovarian cancer. A Canadian model. <i>Gynecologic Oncology</i> , 2019, 153, 87-91.	0.6	11
15	Triple Cytotoxic Therapy for Advanced Ovarian Cancer: A Failed Application, Not a Failed Strategy. <i>Journal of Clinical Oncology</i> , 2009, 27, 1355-1358.	0.8	9
16	Which is the better surgical strategy for newly diagnosed epithelial ovarian cancer. <i>Current Opinion in Oncology</i> , 2011, 23, 501-506.	1.1	7
17	Adjuvant Treatment of Early Ovarian Clear Cell Carcinoma: A Population-Based Study of Whole Abdominal Versus Pelvic Nodal Radiotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 172-180.	2.3	6
18	Time for a Level Playing Field: Inequalities in Regulatory/Approval Processes—The Example of Bevacizumab in Epithelial Ovarian Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1539-1542.	0.8	5

#	ARTICLE	IF	CITATIONS
19	Single or two drug combination therapy as initial treatment for low risk, gestational trophoblastic neoplasia. A Canadian analysis. <i>Gynecologic Oncology</i> , 2020, 157, 367-371.	0.6	5
20	Preoperative Radiotherapy for Inoperable Stage II Endometrial Cancer: Insights into Improving Treatment and Outcomes. <i>Journal of Obstetrics and Gynaecology Canada</i> , 2013, 35, 635-639.	0.3	4
21	Ovarian cancer screening: UKCTOCS trial. <i>Lancet, The</i> , 2016, 387, 2602-2603.	6.3	4
22	Survival Benefit of Adjuvant Radiotherapy: An Analysis of Low-Stage Invasive Ovarian Mucinous Carcinomas. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 1819-1825.	1.2	4
23	Chemotherapy is of Value in Second Line and Beyond, Relapsed High-grade, Serous Epithelial Ovarian Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 379-384.	0.6	3
24	Transformed Lymphoma: Incidence and Long-Term Outcome.. <i>Blood</i> , 2004, 104, 3253-3253.	0.6	3
25	FDG-PET Guided Consolidative Radiotherapy in Patients with Advanced Stage Hodgkin Lymphoma with Residual Abnormalities on Post Chemotherapy CT Scan.. <i>Blood</i> , 2007, 110, 213-213.	0.6	3
26	Follow-Up of Epithelial Ovarian Cancer: Overdue For A Major Rethink. <i>Current Oncology Reports</i> , 2013, 15, 204-206.	1.8	1
27	Outcome in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with CHOP-R Can Be Predicted by Stage and Serum Lactate Dehydrogenase (LDH) Level.. <i>Blood</i> , 2006, 108, 2739-2739.	0.6	0
28	The Role of Platins in Newly Diagnosed Endometrial Cancer. , 2009, , 307-315.		0